[Evidence mapping of traditional Chinese medicine intervention in diabetic retinopathy].

Q3 Pharmacology, Toxicology and Pharmaceutics Zhongguo Zhongyao Zazhi Pub Date : 2024-07-01 DOI:10.19540/j.cnki.cjcmm.20240321.501
Juan Ling, Mei Hu, Yan Wang, Jun Zhou, Zhuo-Lin Xie, Hong-Yong Deng, Xiang-Xia Luo
{"title":"[Evidence mapping of traditional Chinese medicine intervention in diabetic retinopathy].","authors":"Juan Ling, Mei Hu, Yan Wang, Jun Zhou, Zhuo-Lin Xie, Hong-Yong Deng, Xiang-Xia Luo","doi":"10.19540/j.cnki.cjcmm.20240321.501","DOIUrl":null,"url":null,"abstract":"<p><p>This study aims to assess the quality of evidence for the treatment of diabetic retinopathy with traditional Chinese medicine based on the systematic reviews/Meta-analyses of relevant studies. CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, EMbase, and Cochrane Library were searched for the systematic reviews/Meta-analyses of traditional Chinese medicine interventions in diabetic retinopathy published from the inception to November 2023. A Measurement Tool to Assess Systematic Reviews 2(AMSTAR2) scale was used to assess the methodological quality of the included studies. An evidence map was built to present the information on intervention measures, the number of studies included in the systematic reviews/Meta-analyses, research conclusions, and methodological quality assessment results. A total of 51 studies were included. Traditional Chinese medicine interventions accounted for a large proportion of the intervention measures, followed by Chinese patent medicines. The treatment methods mainly included tonifying deficiency, activating blood, and resolving stasis. According to the AMSTAR2 scale assessment results, the descriptions of funding information for included studies, lists of excluded articles, and preliminary research protocols were particularly lacking. The evidence map showed that 48, 2, and 1 studies concluded with beneficial effects, possible beneficial effects, and unclear effects, respectively. On the whole, traditional Chinese medicine demonstrated definite efficacy in the treatment of diabetic retinopathy, while the evidence pre-sents moderate to low quality. It is suggested that higher-quality studies remain to be carried out to provide more evidence.</p>","PeriodicalId":52437,"journal":{"name":"Zhongguo Zhongyao Zazhi","volume":"49 13","pages":"3676-3683"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhongguo Zhongyao Zazhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19540/j.cnki.cjcmm.20240321.501","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

This study aims to assess the quality of evidence for the treatment of diabetic retinopathy with traditional Chinese medicine based on the systematic reviews/Meta-analyses of relevant studies. CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, EMbase, and Cochrane Library were searched for the systematic reviews/Meta-analyses of traditional Chinese medicine interventions in diabetic retinopathy published from the inception to November 2023. A Measurement Tool to Assess Systematic Reviews 2(AMSTAR2) scale was used to assess the methodological quality of the included studies. An evidence map was built to present the information on intervention measures, the number of studies included in the systematic reviews/Meta-analyses, research conclusions, and methodological quality assessment results. A total of 51 studies were included. Traditional Chinese medicine interventions accounted for a large proportion of the intervention measures, followed by Chinese patent medicines. The treatment methods mainly included tonifying deficiency, activating blood, and resolving stasis. According to the AMSTAR2 scale assessment results, the descriptions of funding information for included studies, lists of excluded articles, and preliminary research protocols were particularly lacking. The evidence map showed that 48, 2, and 1 studies concluded with beneficial effects, possible beneficial effects, and unclear effects, respectively. On the whole, traditional Chinese medicine demonstrated definite efficacy in the treatment of diabetic retinopathy, while the evidence pre-sents moderate to low quality. It is suggested that higher-quality studies remain to be carried out to provide more evidence.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[中药干预糖尿病视网膜病变的证据图谱]。
本研究旨在根据相关研究的系统综述/Meta 分析评估中医药治疗糖尿病视网膜病变的证据质量。本研究检索了 CNKI、万方、VIP、SinoMed、PubMed、Web of Science、EMbase 和 Cochrane Library 中从开始至 2023 年 11 月发表的关于中医药干预糖尿病视网膜病变的系统综述/Meta 分析。采用系统综述评估工具2(AMSTAR2)量表评估纳入研究的方法学质量。我们绘制了一张证据图,以展示干预措施、系统综述/Meta 分析所纳入的研究数量、研究结论以及方法学质量评估结果等信息。共纳入 51 项研究。在干预措施中,中药干预占很大比例,其次是中成药。治疗方法主要包括补虚、活血、化瘀。根据AMSTAR2量表评估结果,纳入研究的经费信息说明、排除文章清单和初步研究方案尤为缺乏。证据图谱显示,分别有48、2和1项研究得出了有益效果、可能有益效果和效果不明确的结论。总体而言,中药在治疗糖尿病视网膜病变方面具有确切的疗效,但证据质量为中低水平。建议继续开展更高质量的研究,以提供更多证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Zhongguo Zhongyao Zazhi
Zhongguo Zhongyao Zazhi Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.50
自引率
0.00%
发文量
581
期刊介绍:
期刊最新文献
[Preparation, characterization and antitumor effect of iron-based organic framework nano preparations loaded with piperlongumine]. [Progress and prospects of safety assessment methods of medicinal and food homologous substances]. [Progress and trend of identification of traditional Chinese medicine based on chemical features]. [Protective effect and mechanism of Zuogui Jiangtang Jieyu Formula on damage to hippocampal synaptic microenvironment in rats with diabetes-related depression based on microglia-neuron crosstalk signal CD300f/TLR4]. [Quality standards of medicinal and food homologous substances based on dual attributes].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1